human sw48 colon cancer cell line (Olon Ricerca Bioscience)
90
Structured Review
Olon Ricerca Bioscience
human sw48 colon cancer cell line
Human Sw48 Colon Cancer Cell Line, supplied by Olon Ricerca Bioscience, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+sw48+colon+cancer+cell/human+sw48+dimethylsulfoxide+cell+line/pmc05669927-100-1-31
Average 90 stars, based on 1 article reviews
Human Sw48 Colon Cancer Cell Line, supplied by Olon Ricerca Bioscience, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+sw48+colon+cancer+cell/human+sw48+dimethylsulfoxide+cell+line/pmc05669927-100-1-31
Average 90 stars, based on 1 article reviews
human sw48 colon cancer cell line - by Bioz Stars,
2026-09
90/100 stars
Images
1) Product Images from "Antitumor efficacy of triple monoclonal antibody inhibition of epidermal growth factor receptor (EGFR) with MM151 in EGFR-dependent and in cetuximab-resistant human colorectal cancer cells"
Article Title: Antitumor efficacy of triple monoclonal antibody inhibition of epidermal growth factor receptor (EGFR) with MM151 in EGFR-dependent and in cetuximab-resistant human colorectal cancer cells
Journal: Oncotarget
doi: 10.18632/oncotarget.19797
Figure Legend Snippet: (A-B) Mice were injected subcutaneously in the right flank with SW48 human colon cancer cells, as described in the Materials and Methods. After two weeks (average tumor size 200-300 mm 3 ), mice were treated intraperitoneally with: PBS (phosphate-buffered saline) control, cetuximab, or MM151. The treatment was continued up to 30 weeks after cancer cell injection. Each group consisted of 10 mice. Tumor volumes were measured three times a week. Animals were sacrificed when tumors achieved 2.000 mm 3 in size. Abbreviations: CTR, control; A, median tumor volume (mm 3 ); B, alive mice/total mice; C, number of mice without clinical evidence of progression. (C-D) Mice were monitored for survival until 30 weeks following tumor cell injection. Differences in animal survival among groups were evaluated by use of the Mantel Cox logrank test. Cetuximab versus CTR, MM151 versus CTR, MM151 versus cetuximab (*** p < 0.05).
Techniques Used: Injection, Saline, Control
Figure Legend Snippet: (A-C) SW48, LIM1215 or CACO2 human colon cancer cells were injected subcutaneously into the right flank of seven nude mice, respectively. After two weeks mice were treated with cetuximab (25 mg/Kg once a week) by i.p. injection. Treatment was continued until disease progression. The black arrows indicate the time of progression to cetuximab. At progression mice were treated with MM151 (25 mg/Kg once a week) by i.p. injection. The treatment was continued until 30 weeks following tumor cell injection. At week 30, five out of seven mice were still on treatment with MM151 in the SW48 and LIM1215 xenograft groups as well as four out of seven in the CACO2 xenograft group (as indicated by double asterisk). Abbreviations: PD, progression disease; PR, partial response; SD, stable disease; wks, weeks.
Techniques Used: Injection, Biomarker Discovery
Figure Legend Snippet: (A-C) Tumors were collected at the beginning of cetuximab treatment and at the onset of resistance to cetuximab from mice engrafted with the SW48, LIM1215 and CACO2 cell lines. As control we used one mouse that has not undergone to any type of treatment from the first in vivo experiment. Tumour samples were collected and total cell protein extracts were subjected to immunoblotting with the indicated antibodies, as described in Materials and Methods. Anti-tubulin antibody was used for normalization of protein extract content.
Techniques Used: Control, In Vivo, Western Blot
Related Articles
Staining:Article Title: Regorafenib in combination with silybin as a novel potential strategy for the treatment of metastatic colorectal cancer Article Snippet: The Microscopy:Article Title: Regorafenib in combination with silybin as a novel potential strategy for the treatment of metastatic colorectal cancer Article Snippet: The Standard Deviation:Article Title: Regorafenib in combination with silybin as a novel potential strategy for the treatment of metastatic colorectal cancer Article Snippet: The Fluorescence:Article Title: Regorafenib in combination with silybin as a novel potential strategy for the treatment of metastatic colorectal cancer Article Snippet: The Control:Article Title: Regorafenib in combination with silybin as a novel potential strategy for the treatment of metastatic colorectal cancer Article Snippet: The Positive Control:Article Title: Regorafenib in combination with silybin as a novel potential strategy for the treatment of metastatic colorectal cancer Article Snippet: The Flow Cytometry:Article Title: Regorafenib in combination with silybin as a novel potential strategy for the treatment of metastatic colorectal cancer Article Snippet: The Incubation:Article Title: Regorafenib in combination with silybin as a novel potential strategy for the treatment of metastatic colorectal cancer Article Snippet: The Expressing:Article Title: Regorafenib in combination with silybin as a novel potential strategy for the treatment of metastatic colorectal cancer Article Snippet: The Western Blot:Article Title: Regorafenib in combination with silybin as a novel potential strategy for the treatment of metastatic colorectal cancer Article Snippet: The |
